- 同
- NLPHL
WordNet
- English physiologist who, with Andrew Huxley, discovered the role of potassium and sodium atoms in the transmission of the nerve impulse (1914-1998) (同)Alan Hodgkin, Sir Alan Hodgkin, Alan Lloyd Hodgkin
- English chemist (born in Egypt) who used crystallography to study the structure of organic compounds (1910-1994) (同)Dorothy Hodgkin, Dorothy Mary Crowfoot Hodgkin
- English physician who first described Hodgkins disease (1798-1866) (同)Thomas Hodgkin
- relating to or characterized by or having nodules; "Nodular vaginitis"
- having nodules or occurring in the form of nodules; "nodular ores" (同)nodulated, noduled
- an agranulocytic leukocyte that normally makes up a quarter of the white blood cell count but increases in the presence of infection (同)lymph cell
- a neoplasm of lymph tissue that is usually malignant; one of the four major types of cancer
PrepTutorEJDIC
- 節(ふし)の[ような]
- 優勢な;(…に対して)有力な《+『over』+『名』》 / 最も(ひんぱんに)目につく
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/11/03 19:19:16」(JST)
[Wiki en表示]
| Nodular lymphocyte predominant Hodgkin's lymphoma |
| Classification and external resources |
Micrograph of a lymph node biopsy showing nodular lymphocyte predominant Hodgkin lymphoma, with the Reed-Sternberg cell variant that has a popcorn-shaped nucleus (left-bottom of image). H&E stain.
|
| ICD-10 |
C81.0 |
| ICD-9 |
201.9 |
| ICD-O: |
M9659/3 |
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a form of lymphoma.[1][2]
Hodgkin lymphoma, nodular lymphocyte predominant (low power view). Notice the nodular architecture and the areas of "mottling".(H&E)
Hodgkin lymphoma, nodular lymphocyte predominant (high power view). Notice the presence of L&H cells, also known as "popcorn cells". (H&E)
It is no longer classified as a form of classic Hodgkin's lymphoma (HL). This is because the Reed-Sternberg Cell (RSC) variants (popcorn cells) that characterize this form of the disease invariably express B lymphocyte markers such as CD20 (thus making NLPHL an unusual form of B cell lymphoma), and that (unlike classic HL) NLPHL may progress to diffuse large B cell lymphoma.
There are small but clear differences in prognosis between the various forms. Lymphocyte predominant HL is an uncommon subtype composed of vague nodules of numerous reactive lymphocytes admixed with large popcorn-shaped RSC. Unlike classic RSC, the non-classic popcorn-shaped RS cells of NLPHL are CD15 and CD30 negative while positive for the B cell marker CD20. The anti-CD20 monoclonal antibody Rituximab has been used in lymphocyte predominant Hodgkin's lymphoma with encouraging results.[3]
BCL6 gene rearrangements have been frequently observed.[4][5]
See also[edit]
- Progressive transformation of germinal centers
References[edit]
- ^ Renné C, Martín-Subero JI, Hansmann ML, Siebert R (August 2005). "Molecular Cytogenetic Analyses of Immunoglobulin Loci in Nodular Lymphocyte Predominant Hodgkin's Lymphoma Reveal a Recurrent IGH-BCL6 Juxtaposition". J Mol Diagn 7 (3): 352–6. doi:10.1016/S1525-1578(10)60564-8. PMC 1867541. PMID 16049307.
- ^ Achten R, Verhoef G, De Wolf-Peeters C (December 2003). "The importance of follow-up biopsies of clinically suspicious lymphadenopathy in nodular lymphocyte predominant Hodgkin's lymphoma". Haematologica 88 (12): 1431–2. PMID 14688002.
- ^ Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA (2011). "Rituximab in Hodgkin lymphoma: Is the target always a hit?". Cancer Treat Rev 37 (5): 385–90. doi:10.1016/j.ctrv.2010.11.005. PMID 21183282.
- ^ Wlodarska I, Stul M, De Wolf-Peeters C, Hagemeijer A (August 2004). "Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma". Haematologica 89 (8): 965–72. PMID 15339680.
- ^ Wlodarska I, Nooyen P, Maes B, et al. (January 2003). "Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma". Blood 101 (2): 706–10. doi:10.1182/blood-2002-05-1592. PMID 12393409.
|
Hematological malignancy/leukemia histology (ICD-O 9590–9989, C81–C96, 200–208)
Lymphoid/Lymphoproliferative, Lymphomas/Lymphoid leukemias (9590–9739, 9800–9839)
|
|
B cell
(lymphoma,
leukemia)
(most CD19
|
|
By development/
marker
|
|
TdT+
|
- ALL (Precursor B acute lymphoblastic leukemia/lymphoma)
|
|
|
CD5+
|
mantle zone (Mantle cell)
|
|
|
CD22+
|
- Prolymphocytic
- CD11c+ (Hairy cell leukemia)
|
|
|
CD79a+
|
- germinal center/follicular B cell (Follicular
- Burkitt's
- GCB DLBCL
- Primary cutaneous follicular lymphoma)
marginal zone/marginal-zone B cell (Splenic marginal zone
- MALT
- Nodal marginal zone
- Primary cutaneous marginal zone lymphoma)
|
|
|
RS (CD15+, CD30+)
|
- Classic Hodgkin's lymphoma (Nodular sclerosis)
- CD20+ (Nodular lymphocyte predominant Hodgkin's lymphoma)
|
|
|
PCDs/PP
(CD38+/CD138+)
|
- see immunoproliferative immunoglobulin disorders
|
|
|
|
By infection
|
- KSHV (Primary effusion)
- EBV (Lymphomatoid granulomatosis
- Post-transplant lymphoproliferative disorder)
- HIV (AIDS-related lymphoma)
- Helicobacter pylori (MALT lymphoma)
|
|
|
Cutaneous
|
- Diffuse large B-cell lymphoma
- Intravascular large B-cell lymphoma
- Primary cutaneous marginal zone lymphoma
- Primary cutaneous immunocytoma
- Plasmacytoma
- Plasmacytosis
- Primary cutaneous follicular lymphoma
|
|
|
|
T/NK
|
T cell
(lymphoma,
leukemia)
(most CD3
|
|
By development/
marker
|
- TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma)
- prolymphocyte (Prolymphocytic)
- CD30+ (Anaplastic large-cell lymphoma
- Lymphomatoid papulosis type A)
|
|
|
Cutaneous
|
|
MF+variants
|
- indolent: Mycosis fungoides
- Pagetoid reticulosis
- Granulomatous slack skin
aggressive: Sézary's disease
- Adult T-cell leukemia/lymphoma
|
|
|
Non-MF
|
- CD30-: Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma
- Pleomorphic T-cell lymphoma
- Lymphomatoid papulosis type B
CD30+: CD30+ cutaneous T-cell lymphoma
- Secondary cutaneous CD30+ large cell lymphoma
- Lymphomatoid papulosis type A
|
|
|
|
Other peripheral
|
- Hepatosplenic
- Angioimmunoblastic
- Enteropathy-associated T-cell lymphoma
- Peripheral T-cell lymphoma-Not-Otherwise-Specified (Lennert lymphoma)
- Subcutaneous T-cell lymphoma
|
|
|
By infection
|
- HTLV-1 (Adult T-cell leukemia/lymphoma)
|
|
|
|
NK cell/
(most CD56)
|
- Aggressive NK-cell leukemia
- Blastic NK cell lymphoma
|
|
|
T or NK
|
- EBV (Extranodal NK-T-cell lymphoma/Angiocentric lymphoma)
- Large granular lymphocytic leukemia
|
|
|
|
Lymphoid+myeloid
|
- Acute biphenotypic leukaemia
|
|
|
Lymphocytosis
|
- Lymphoproliferative disorders (X-linked lymphoproliferative disease
- Autoimmune lymphoproliferative syndrome)
- Leukemoid reaction
- Diffuse infiltrative lymphocytosis syndrome
|
|
|
| Cutaneous lymphoid hyperplasia |
- Cutaneous lymphoid hyperplasia
- with bandlike and perivascular patterns
- with nodular pattern
- Jessner lymphocytic infiltrate of the skin
|
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Late mortality among 5-year survivors of early onset cancer: A population-based register study.
- Kero AE1, Järvelä LS, Arola M, Malila N, Madanat-Harjuoja LM, Matomäki J, Lähteenmäki PM.
- International journal of cancer. Journal international du cancer.Int J Cancer.2015 Apr;136(7):1655-64. doi: 10.1002/ijc.29135. Epub 2014 Aug 22.
- To date, only few studies have been published documenting late mortality among early onset cancer survivors, especially regarding young adulthood (YA) malignancies. Our nation-wide population-based registry study provides information concerning cause-specific long-term mortality among 16,769 5-year
- PMID 25110999
- Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe.
- Hanly P1, Soerjomataram I, Sharp L.
- International journal of cancer. Journal international du cancer.Int J Cancer.2015 Feb 15;136(4):E136-45. doi: 10.1002/ijc.29105. Epub 2014 Sep 4.
- Every cancer-related death in someone of working age represents an economic loss to society. To inform priorities for cancer control, we estimated costs of lost productivity due to premature cancer-related mortality across Europe, for all cancers and by site, gender, region and country. Cancer death
- PMID 25066804
- Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.
- Zoellner AK1, Fritsch S1, Prevalsek D1, Engel N1, Hubmann M1, Reibke R1, Rieger CT1, Hellmuth JC1, Haas M1, Mumm F1, Herold T1, Ledderose G1, Hiddemann W1, Dreyling M1, Hausmann A2, Tischer J1.
- Bone marrow transplantation.Bone Marrow Transplant.2015 Feb 2. doi: 10.1038/bmt.2014.328. [Epub ahead of print]
- Prognosis is poor for patients with biologically aggressive Non-Hodgkin lymphoma (NHL), refractory to chemotherapy or relapsed after autologous transplantation, especially when no disease control before allogeneic transplantation is achieved. In 16 patients (median age 53, median prior regimes 5) wi
- PMID 25642765
Japanese Journal
- 結節性リンパ球優位型ホジキンリンパ腫の診断と治療 (造血器腫瘍学 : 基礎と臨床の最新研究動向) -- (リンパ系腫瘍の臨床)
Related Links
- ホジキンリンパ腫（ホジキンリンパしゅ、英: Hodgkin's lymphoma; HL）は、悪性リンパ腫 の一分類で、病理組織学的にはホジキン細胞 (Hodgkin ... 結節性リンパ球優位型 ホジキンリンパ腫 (Nodular lymphocyte predominant Hodgkin's lymphoma : NLPHL ) ...
★リンクテーブル★
[★]
- 英
- nodular lymphocyte-predominant Hodgkin lymphoma, NLPHL
- 関
- ホジキンリンパ腫
参考
- http://www.med.osaka-cu.ac.jp/labmed/page106.html
[★]
- 同
- nodular lymphocyte-predominant Hodgkin lymphoma
[★]
- 優勢な、有力な、支配的な。すぐれた、卓越した。広く行われる。
- 関
- chiefly、dominance、dominant、dominantly、main、mainly、major、mostly、predominance、predominantly、predominately、preponderance、prevailing、primarily、principally
[★]
- 関
- nodal、nodosity、nodule、tophaceous、tubercular、varicose
[★]
リンパ球
- 同
- lymphocytes＆development